PPAR-γ:: therapeutic target for ischemic stroke

被引：144

作者：

Culman, Juraj ^{[1
]}

Zhao, Yi ^{[1
]}

Gohlke, Peter ^{[1
]}

Herdegen, Thomas ^{[1
]}

机构：

[1] Univ Hosp Schleswig Holstein, Inst Pharmacol, D-24105 Kiel, Germany

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2007年 / 28卷 / 05期

关键词：

D O I：

10.1016/j.tips.2007.03.004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The peroxisome proliferator activated receptors (PPARs), which belong to the nuclear receptor superfamily, are key regulators of glucose and fat metabolism. The PPAR-gamma isoform is involved in the regulation of cellular glucose uptake, protection against atherosclerosis and control of immune reactions. In addition, the activation of PPAR-gamma effectively attenuates neurodegenerative and inflammatory processes in the brain. Here, we review a novel aspect of beneficial and clinically relevant PPAR-gamma actions: neuroprotection against ischemic injury mediated by intracerebral PPAR-gamma, which is expressed in neurons and microglia. Together with the recent observation that the PPAR-gamma ligand pioglitazone reduces the incidence of stroke in patients with type 2 diabetes, this review supports the concept that activators of PPAR-gamma are effective drugs against ischemic injury.

引用

页码：244 / 249

页数：6

共 58 条

[1] Guidelines for the early management of patients with ischemic stroke - A scientific statement from the Stroke Council of the American Stroke Association [J].

Adams, HP ;

Adams, RJ ;

Brott, T ;

del Zoppo, GJ ;

Furlan, A ;

Goldstein, LB ;

Grubb, RL ;

Higashida, R ;

Kidwell, C ;

Kwiatkowski, TG ;

Marler, JR ;

Hademenos, GJ .

STROKE, 2003, 34 (04) :1056-1083

[2] Role of PPAR-γ ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells [J].

Aoun, P ;

Simpkins, JW ;

Agarwal, N .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (07) :2999-3004

[3] FOXO1 represses peroxisome proliferator-activated receptor-γ1 and -γ2 gene promoters in primary adipocytes -: A novel paradigm to increase insulin sensitivity [J].

Armoni, Michal ;

Harel, Chava ;

Karni, Shiri ;

Chen, Hui ;

Bar-Yoseph, Fabiana ;

Ver, Marel R. ;

Quon, Michael J. ;

Karnieli, Eddy .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (29) :19881-19891

[4] Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes [J].

Belcher, G ;

Lambert, C ;

Edwards, G ;

Urquhart, R ;

Matthews, DR .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 70 (01) :53-62

[5] Peroxisome proliferator-activated receptor γ regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo [J].

Benkirane, K ;

Viel, ÉC ;

Amiri, F ;

Schiffrin, EL .

HYPERTENSION, 2006, 47 (01) :102-108

[6] PPARs: therapeutic targets for metabolic disease [J].

Berger, JP ;

Akiyama, TE ;

Meinke, PT .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2005, 26 (05) :244-251

[7] PPAR-γ agonists as regulators of microglial activation and brain inflammation [J].

Bernardo, A ;

Minghetti, L .

CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (01) :93-109

[8] Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes [J].

Blaschke, F ;

Takata, Y ;

Caglayan, E ;

Law, RE ;

Hsueh, WA .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (01) :28-40

[9] PPAR:: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases [J].

Bordet, R. ;

Ouk, T. ;

Petrault, O. ;

Gele, P. ;

Gautier, S. ;

Laprais, M. ;

Deplanque, D. ;

Duriez, P. ;

Staels, B. ;

Fruchart, J. C. ;

Bastide, M. .

BIOCHEMICAL SOCIETY TRANSACTIONS, 2006, 34 :1341-1346

[10] Inhibition of tumor-necrosis-factor-α induced endothelial cell activation by a new class of PPAR-γ agonists -: An in vitro study showing receptor-independent effects [J].

Calabrò, P ;

Samudio, I ;

Safe, SH ;

Willerson, JT ;

Yeh, ETH .

JOURNAL OF VASCULAR RESEARCH, 2005, 42 (06) :509-516

← 1 2 3 4 5 6 →